Skip to content


An engine for antibody drug discovery and development

First Investment: 2018
EXIT - Nasdaq: ABCL

Antibody therapies represent a blockbuster drug category because they can treat diseases from arthritis to eczema to cancer. But finding antibodies that can be developed into successful new medicines is still a slow, expensive, high-risk process. AbCellera has combined single-cell analysis with modern computation and other tools to create a better search engine for the immune system, allowing rapid iden­ti­fi­ca­tion of therapeutic antibodies against threats such as the SARS-CoV‑2 virus.

News & Insights

In The Media

Explore Companies